Program Cancer
Against Itself

What is the Holy Grail in cancer?

↓

Kill the bad cells,
but don't kill the good cells

"Malignant growth and normal growth are so genetically intertwined that  unbraiding  the two might be one of the most  significant  scientific challenges faced  by our species ."

Prologue in The Emperor Of All Maladies

‍Pulitzer Prize 2011, Siddhartha Mukherjee

Earli uses AI
to build the first genetic switches
that program  only  cancer cells
to make their own therapies

See Earli's science →

News

All news →
BiotechTV:
How Earli developed AI-designed genetic switches that program cancer cells to make their own immune
TBPN -
Earli announces next $44M in funding
NPR BioTech Nation - Podcast:
Can Cancer Cells Be Turned Against Themselves? Cyriac Roeding & Dr. David Suhy
White House Cancer Moonshot:
Earli highlighted as a key initiative
S. Korea #1 Business Newspaper Maeil:
Ordering Cancer Cells to "Self-Destruct"? U.S. Biotech Firm Unveils Breakthrough Gene Technology
The Scientist - Interview:
Turning Tumors Against Themselves From the Inside
Fast Company:
A Cancer Genius Died From Cancer. His Startup is Getting Revenge
Genetic Engineering & Biotechnology News:
Earli Detection: “Synthetic” Biomarkers Light Up Hidden...
Drug Discovery Trends:
Earli and Accenture Partner in Quest to Turn Cancer Against Itself
Biospace -
Opinion: Trump Must Make Biotech Innovations a National Priority
Newsweek:
One Glaring Problem in the U.S. Plan to Reduce Cancer Deaths | Opinion
CGT Live:
Using DNA Nanoplasmids as a Diagnostic Tool in Cancer
Tech Target:
Using Synthetic Biomarkers for Early Cancer Detection
Entrepreneur:
The Story Of Earli
Pharmaceutical Technology:
Accenture Invests in Earli to Advance Early Cancer Detection Tech
The Sydney Morning Herald:
Australia’s ‘High Quality’ Clinical Trials Lure Silicon Valley...
World Economic Forum:
World Economic Forum Names Earli A Global Innovator
Fast Company:
World Changing Ideas - Earli The Only Early Cancer Detection Firm in List of 2021
WIRED:
A Proactive Way to Detect Cancer at Its Earliest Stages
The Atlantic:
A Medical Revolution Too Late for the Man Who Started It
Nikkei:
Cancer treatment control over early detection (Japaneses Language)
Tough Tech Today:
Exposing Cancer, Feat. Cyriac Roeding of Earli
S. Korea: Medical Newspaper
A new frontier in cancer treatment: controlling cancer cells to self-destruct (in Korean Language)
German Business Week (Wirtschaftswoche):
The Inventor Is Dead, Long Live The Invention (German)
Forbes:
This Company Raised $40 Million To Make Tumors Reveal Themselves
Business Wire:
Earli Raises $40 Million Series A Funding Led by...
Stat News:
New Ways to Detect Cancer Early Will Help Pave The Way for Precision Health
TBPN -
Earli announces next $44M in funding
NPR BioTech Nation - Podcast:
Can Cancer Cells Be Turned Against Themselves? Cyriac Roeding & Dr. David Suhy
White House Cancer Moonshot:
Earli highlighted as a key initiative
S. Korea #1 Business Newspaper Maeil:
Ordering Cancer Cells to "Self-Destruct"? U.S. Biotech Firm Unveils Breakthrough Gene Technology
The Scientist - Interview:
Turning Tumors Against Themselves From the Inside
Fast Company:
A Cancer Genius Died From Cancer. His Startup is Getting Revenge
Genetic Engineering & Biotechnology News:
Earli Detection: “Synthetic” Biomarkers Light Up Hidden...
Drug Discovery Trends:
Earli and Accenture Partner in Quest to Turn Cancer Against Itself
Biospace -
Opinion: Trump Must Make Biotech Innovations a National Priority
Newsweek:
One Glaring Problem in the U.S. Plan to Reduce Cancer Deaths | Opinion
CGT Live:
Using DNA Nanoplasmids as a Diagnostic Tool in Cancer
Tech Target:
Using Synthetic Biomarkers for Early Cancer Detection
Entrepreneur:
The Story Of Earli
Pharmaceutical Technology:
Accenture Invests in Earli to Advance Early Cancer Detection Tech

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Close-pop-up

Program Cancer Against Itself.™

Science

About

News

Join

© 2023 Earli Inc.
Contact →
© 2023 Earli Inc.